Plus   Neg

KYTH Talks Of Double Chin Fix, REGN's Skin Care Works, IMUN Gives Up On ITL Suit


KYTHERA Biopharmaceuticals Inc. (KYTH) on Saturday announced interim results from a phase IIIb, which showed that its investigational drug ATX-101 is well-tolerated and effective in reducing unwanted submental fat, commonly known as double chin. Topline results from this study were announced last November.

KYTH closed Friday's trading at $25.12, down 3.61%.

Sanofi (SNY) and Regeneron Pharmaceuticals Inc. (REGN) on Saturday announced pooled data from two phase 1b trials with Dupilumab, which demonstrated the compound's safety profile. The studies also showed that treatment with four weekly subcutaneous injections of Dupilumab at either 150 mg or 300mg per week, significantly improved the signs and symptoms of patients with moderate-to-severe atopic dermatitis whose disease was not adequately controlled with topical medications.

The company expects to report additional data from a 12-week, phase 2a trial in atopic dermatitis, and commence a larger phase 2b trial with Dupilumab in patients with atopic dermatitis, later this year.

DARA BioSciences Inc. (DARA) has appointed Haywood Cochrane Jr. as chairman of its board of directors and Paul Richardson as a new board member.

The company submitted an Orphan Drug Application to the FDA for KRN5500, a phase II compound to treat a painful form of chronic chemotherapy-induced peripheral neuropathy, or CCIPN, last November. Currently, there are no approved treatments for CCIPN.

DARA closed Friday's trading at $0.98, down 2.97%.

Endocyte Inc. (ECYT) on Friday announced a new analysis demonstrating that the investigational diagnostic imaging agent Etarfolatide can identify ovarian cancer and non-small cell lung cancer patients who could benefit from folate receptor-targeted therapeutics, such as the novel investigational cancer candidate Vintafolide.

Vintafolide and Etarfolatide are currently being evaluated in a phase 3 clinical trial for platinum-resistant ovarian cancer, dubbed PROCEED trial, and a phase 2b trial in patients with NSCLC, known as TARGET trial.

The marketing authorization application filings for Vintafolide and Etarfolatide are under review by the European Medicines Agency.

ECYT closed Friday's trading 0.93% higher at $9.74.

EntreMed Inc. (ENMD) has agreed to sell an aggregate of 4.49 million shares of its common stock and warrants to purchase 2.25 million shares of its common stock in a registered direct offering. Each unit, consisting of one share of common stock and a warrant to purchase 0.5 share of common stock will be sold for a purchase price of $2.40. The company expects to receive net proceeds of about $10.3 million from the offering.

ENMD closed Friday's trading 10.17% lower at $2.65.

Immunovative Inc. (IMUN) on Friday announced that it has voluntarily dismissed its lawsuit against Immunovative Therapies Ltd., or ITL, and Michael Har-Noy, President and CEO of Immunovative Therapies Ltd.

Immunovative filed a lawsuit against Immunovative Therapies in January of this year for wrongful termination of a License Agreement that was entered into in Dec.2011.

Now that Immunovative Inc. has dismissed the lawsuit, as part of this resolution, the parties agree that the License Agreement is terminated. Immunovative Inc said it will also change its name and stock symbol to reflect its ongoing business.

VentriPoint Diagnostics (VPT.V) on Friday announced that its 510(k) submission for right heart analysis in Pulmonary Arterial Hypertension has been accepted for review by FDA.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Follow RTT